Pessary - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The pessary market size is expected to grow from USD 473.08 million in 2025 to USD 494.98 million in 2026 and is forecast to reach USD 620.32 million by 2031 at 4.63% CAGR over 2026-2031. This report is Segmented by Type (Ring, Gellhorn, Donut, Cube, Other Types), Material (Medical-Grade Silicone, Thermoplastic Elastomer, and More), Application (POP Stage I-II, and More), End User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Pessary Market Trends and Insights

Growing Prevalence of POP & Urinary Incontinence

Pelvic organ prolapse (POP) cases are projected to climb 46% by 2050, with the steepest gains in women aged 70-79. Quality-of-life studies show 56% of affected women experience incontinence and 52% develop prolapse, highlighting unmet need. Annual U.S. surgical costs already top USD 1.523 billion, heightening payer interest in non-surgical alternatives. Eighty-two percent of prolapse surgeries now occur in ambulatory centers, settings that readily integrate pessary fitting. These clinical and economic facts underpin steady demand for conservative therapy, strengthening the long-term foundation of the pessary market. Source: Taryn Hall, “Pelvic Floor Disorder Symptom Burden Survey,” Frontiers in Public Health, frontiersin.org

Shift Toward Non-Surgical Outpatient Management

Prospective studies record 40% symptom relief in voiding, 38% drop in urgency, and 29% reduction in urge incontinence among pessary users. The American Urogynecologic Society’s 2024 consensus formalized care pathways, addressing earlier guideline gaps. Ergonomic upgrades - such as collapsible rings - cut insertion pain and support self-care. Tele-urogynecology platforms now permit remote prescribing, with follow-up protocols embedded in software workflows. Reimbursement recognition through HCPCS coding further validates outpatient conservative management as both clinically and economically viable.

Patient Discomfort, Complications & Fear

Recent multicenter work notes a 21% complication incidence; expulsion makes up 40.8% and pain 26.6% of those events. Surgical resolution becomes necessary in 34.2% of complex cases, shaping clinician caution. Up to 30% of eligible women decline a trial due to anxiety over discomfort or dislodgment. Anatomical constraints - vaginal length under 7.5 cm - predict discontinuation yet require specialized assessment tools not ubiquitous in primary care. Cultural taboos further dampen uptake in certain geographies. Although collapsible and customized devices mitigate many issues, price and practitioner familiarization lag behind technical possibilities.

Other drivers and restraints analyzed in the detailed report include:

• Rising Awareness & Women-Health Initiatives
• Advances in Medical-Grade Silicone & Ergonomic Design
• Limited Reimbursement Coverage

Segment Analysis

Ring pessaries generated 45.98% of pessary market share in 2025, underscoring deep provider familiarity and broad indication coverage. Cube devices, however, are projected to outpace the broader pessary market at a 6.12% CAGR to 2031, favored for advanced prolapse scenarios. Gellhorn and donut variants fill specific anatomical niches, whereas emerging collapsible and 3D-printed models inhabit the technological frontier.

Custom manufacturing is redefining clinical protocols. Cosm Medical’s FDA-cleared Gynethotics platform delivers anatomical imaging, AI-assisted design and in-clinic 3D printing, a process that trims trial-and-error timelines and improves fit. As printing costs fall and clinical data mount, ring dominance could erode. Yet ring designs still benefit from lowest unit cost and entrenched reimbursement coding, positioning them as baseline solutions even as personalization gains ground across the pessary market.

Medical-grade silicone retained 78.02% of the pessary market size in 2025 owing to unrivaled biocompatibility, tensile resilience, and sterilizability. Latex/rubber’s 6.45% CAGR reflects health-system cost constraints and patient demand for lower-priced options in emerging regions. Thermoplastic elastomers offer recyclability advantages but remain niche. Bio-resorbable polymers and composite 3D-prints lie at the R&D horizon, melding sustainability with individualized geometry.

EU environmental scoring is compelling procurement teams to weigh carbon footprint and end-of-life disposal alongside clinical efficacy. Health systems that adopt lifecycle tenders could gradually divert volume toward greener materials. Nevertheless, silicone’s legacy validation keeps regulatory hurdles low and adoption friction minimal, sustaining its near-term primacy within the pessary market.

Complete Report Scope:

• By Product
  • Restorative Materials
    • Direct Restorative Materials
    • Indirect Restorative Materials
    • Biomaterials
    • Bonding Agents / Adhesives
    • Impression Materials
  • Implants
  • Prosthetics
  • Restorative Equipment
    • CAD/CAM Systems
    • Handpieces
    • Rotary Instruments
    • Casting Equipment
    • Other Restorative Equipments
• By End-User
  • Dental Hospitals & Clinics
  • Dental Labs
  • Other End-Users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America led the pessary market with a 38.11% revenue share in 2025, buoyed by widespread urogynecology networks, targeted women-health funding and clear FDA pathways. The U.S. government’s USD 100 million research allocation is fostering clinical trials and provider training that feed demand. CooperSurgical’s 2024 revenue reached USD 1.286 billion, proof that established players can still grow 10% by harnessing clinician relationships and reimbursement savvy. Insurer fee compression and coverage disparities pose lingering obstacles, yet telehealth’s regulatory normalization broadens patient reach. Canada and Mexico add incremental upside through healthcare system modernization.

Asia-Pacific is forecast to outpace all regions at a 5.18% CAGR to 2031. Aging demographics in Japan and South Korea mirror Western trends, while China’s middle-class expansion and hospital build-outs unlock volume potential. The region’s medtech revenues could touch USD 225 billion by 2030, supplying favorable context for the pessary market. Regulatory heterogeneity and cultural stigma complicate rollout, but social-commerce integration and rising FemTech literacy are easing adoption. Private-equity investment and public infrastructure funding in 2024 fortified domestic supply chains, setting a foundation for sustained gains.

Europe’s universal healthcare coverage and evidence-based practice culture support stable, mid-single-digit growth. EU MDR and IVDR quality thresholds elevate compliance costs yet protect incumbents with established QMS footprints. Sustainability directives press manufacturers toward biodegradable inputs and circular-economy packaging, potentially sparking material innovation. Market conditions in the Middle East & Africa and South America remain nascent but promising, dependent on infrastructure upgrades, clinician education and broadened payer coverage to unlock their share of the global pessary market.

List of Companies Covered in this Report:

• 3M
• Dentsply Sirona
• Envista
• Mitsui Chemicals
• Straumann Group
• ZimVie
• Septodont
• Ivoclar Vivadent
• Coltene Holding
• GC Corporation
• Henry Schein
• Align Technology
• Planmeca
• Carestream Dental
• VOCO
• SHOFU Inc.
• Kavo Dental
• Kuraray Noritake Dental Inc.
• Bisco, Inc.
• SDI
• DMG Chem-Pharma-Fabrik GmbH
• Nobel Biocare Services

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support